Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed Enterprise Value for 5 consecutive years, with -$165.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 32.03% year-over-year to -$165.6 million, compared with a TTM value of -$165.6 million through Dec 2025, up 32.03%, and an annual FY2025 reading of -$165.6 million, up 32.03% over the prior year.
- Enterprise Value was -$165.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from -$352.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$141.1 million in Q1 2024 and bottomed at -$379.5 million in Q1 2025.
- Average Enterprise Value over 5 years is -$217.3 million, with a median of -$191.3 million recorded in 2022.
- The sharpest move saw Enterprise Value surged 44.91% in 2022, then crashed 169.03% in 2025.
- Year by year, Enterprise Value stood at -$182.2 million in 2021, then fell by 4.61% to -$190.6 million in 2022, then dropped by 8.27% to -$206.4 million in 2023, then decreased by 18.05% to -$243.6 million in 2024, then soared by 32.03% to -$165.6 million in 2025.
- Business Quant data shows Enterprise Value for KNSA at -$165.6 million in Q4 2025, -$352.1 million in Q3 2025, and -$192.0 million in Q2 2025.